Try the modernized beta website. Learn more about the modernization effort.
Working… Menu

A Study of Osimertinib With or Without Chemotherapy as 1st Line Treatment in Patients With Mutated Epidermal Growth Factor Receptor Non-Small Cell Lung Cancer (FLAURA2) (FLAURA2)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT04035486
Recruitment Status : Active, not recruiting
First Posted : July 29, 2019
Last Update Posted : April 18, 2022
Information provided by (Responsible Party):